Secukinumab 150 mg (2 injections per dose ( DrugBank: Secukinumab )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
269化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群1

269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群


臨床試験数 : 23 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 106
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04274166
(ClinicalTrials.gov)
May 202112/2/2020Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumThe Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumPyoderma GangrenosumDrug: secukinumab 150 mg (2 injections per doseWake Forest University Health SciencesNovartisWithdrawn18 Years75 YearsAll0Phase 2United States